Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Correlation between plasma concentration ratios of SN-38 glucuronide and SN-38 and neutropenia induction in patients with colorectal cancer and wild-type UGT1A1 gene.

Hirose K, Kozu C, Yamashita K, Maruo E, Kitamura M, Hasegawa J, Omoda K, Murakami T, Maeda Y.

Oncol Lett. 2012 Mar;3(3):694-698. Epub 2011 Dec 22.

2.

Usefulness of one-point plasma SN-38G/SN-38 concentration ratios as a substitute for UGT1A1 genetic information after irinotecan administration.

Hirose K, Yamashita K, Takada H, Kaneda N, Fukami K, Maruo E, Kitamura M, Hasegawa J, Maeda Y.

Int J Clin Oncol. 2014 Apr;19(2):397-402. doi: 10.1007/s10147-013-0558-1. Epub 2013 Apr 19.

PMID:
23605141
3.

Shengjiang Xiexin Decoction Alters Pharmacokinetics of Irinotecan by Regulating Metabolic Enzymes and Transporters: A Multi-Target Therapy for Alleviating the Gastrointestinal Toxicity.

Guan HY, Li PF, Wang XM, Yue JJ, He Y, Luo XM, Su MF, Liao SG, Shi Y.

Front Pharmacol. 2017 Oct 27;8:769. doi: 10.3389/fphar.2017.00769. eCollection 2017.

4.

[Assessment of total bilirubin or SN-38/SN-38G ratio as a predictor of severe irinotecan toxicity].

Tanaka H, Saito K, Mino K, Izumi K, Harada M, Isobe H.

Gan To Kagaku Ryoho. 2009 Sep;36(9):1505-9. Japanese.

PMID:
19755821
5.

Polymorphisms of UDP-glucuronosyltransferase and pharmacokinetics of irinotecan.

Ando Y, Ueoka H, Sugiyama T, Ichiki M, Shimokata K, Hasegawa Y.

Ther Drug Monit. 2002 Feb;24(1):111-6.

PMID:
11805731
6.

Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer.

Araki K, Fujita K, Ando Y, Nagashima F, Yamamoto W, Endo H, Miya T, Kodama K, Narabayashi M, Sasaki Y.

Cancer Sci. 2006 Nov;97(11):1255-9. Epub 2006 Sep 12.

7.

Effects of bevacizumab on plasma concentration of irinotecan and its metabolites in advanced colorectal cancer patients receiving FOLFIRI with bevacizumab as second-line chemotherapy.

Horita Y, Yamada Y, Hirashima Y, Kato K, Nakajima T, Hamaguchi T, Shimada Y.

Cancer Chemother Pharmacol. 2010 Feb;65(3):467-71. doi: 10.1007/s00280-009-1051-4. Epub 2009 Jun 25.

PMID:
19554330
8.

A pilot study on the safety of combining chrysin, a non-absorbable inducer of UGT1A1, and irinotecan (CPT-11) to treat metastatic colorectal cancer.

Tobin PJ, Beale P, Noney L, Liddell S, Rivory LP, Clarke S.

Cancer Chemother Pharmacol. 2006 Feb;57(3):309-16. Epub 2005 Jul 8.

PMID:
16003560
9.

Pharmacokinetics, safety, and efficacy of FOLFIRI plus bevacizumab in Japanese colorectal cancer patients with UGT1A1 gene polymorphisms.

Suenaga M, Fuse N, Yamaguchi T, Yamanaka Y, Motomura S, Matsumoto H, Hamamoto Y, Mizunuma N, Doi T, Hatake K, Iwasaki J, Ohtsu A.

J Clin Pharmacol. 2014 May;54(5):495-502. doi: 10.1002/jcph.246. Epub 2014 Jan 2.

PMID:
24382596
10.

Panipenem does not alter the pharmacokinetics of the active metabolite of irinotecan SN-38 and inactive metabolite SN-38 glucuronide (SN-38G) in rats.

Kato A, Ueyama J, Abe F, Hotta K, Tsukiyama I, Oshima T, Kondo F, Saito H, Hasegawa T.

Anticancer Res. 2011 Sep;31(9):2915-22.

PMID:
21868538
11.

Streptomycin alleviates irinotecan-induced delayed-onset diarrhea in rats by a mechanism other than inhibition of β-glucuronidase activity in intestinal lumen.

Kurita A, Kado S, Matsumoto T, Asakawa N, Kaneda N, Kato I, Uchida K, Onoue M, Yokokura T.

Cancer Chemother Pharmacol. 2011 Jan;67(1):201-13. doi: 10.1007/s00280-010-1310-4. Epub 2010 Mar 31.

PMID:
20354702
12.

Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D.

Jinno H, Tanaka-Kagawa T, Hanioka N, Saeki M, Ishida S, Nishimura T, Ando M, Saito Y, Ozawa S, Sawada J.

Drug Metab Dispos. 2003 Jan;31(1):108-13.

13.

Determination of irinotecan, SN-38 and SN-38 glucuronide using HPLC/MS/MS: Application in a clinical pharmacokinetic and personalized medicine in colorectal cancer patients.

Atasilp C, Chansriwong P, Sirachainan E, Reungwetwattana T, Puangpetch A, Prommas S, Sirilerttrakul S, Rerkarmnuaychoke B, Wongwaisayawan S, Sukasem C.

J Clin Lab Anal. 2017 Apr 10. doi: 10.1002/jcla.22217. [Epub ahead of print]

PMID:
28393405
14.

Individual differences in rate-limiting reactions during metabolism of irinotecan hydrochloride.

Morimoto S, Matsuura I, Shono Y, Horiuchi T, Nakajima Y, Miyabe T, Hachino Y, Hasegawa K, Matsuyama K, Fujita Y, Tabuse K.

Gan To Kagaku Ryoho. 2009 Jul;36(7):1135-40.

PMID:
19620803
15.
16.

Association between the low-dose irinotecan regimen-induced occurrence of grade 4 neutropenia and genetic variants of UGT1A1 in patients with gynecological cancers.

Moriya H, Saito K, Helsby N, Sugino S, Yamakage M, Sawaguchi T, Takasaki M, Kato H, Kurosawa N.

Oncol Lett. 2014 Jun;7(6):2035-2040. Epub 2014 Apr 8.

17.

Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks.

Rothenberg ML, Kuhn JG, Schaaf LJ, Rodriguez GI, Eckhardt SG, Villalona-Calero MA, Rinaldi DA, Hammond LA, Hodges S, Sharma A, Elfring GL, Petit RG, Locker PK, Miller LL, von Hoff DD.

Ann Oncol. 2001 Nov;12(11):1631-41.

PMID:
11822765
18.

Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer.

Canal P, Gay C, Dezeuze A, Douillard JY, Bugat R, Brunet R, Adenis A, Herait P, Lokiec F, Mathieu-Boue A.

J Clin Oncol. 1996 Oct;14(10):2688-95.

PMID:
8874328
19.

Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea.

Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE, Ratain MJ.

Cancer Res. 1994 Jul 15;54(14):3723-5.

20.

Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.

Innocenti F, Kroetz DL, Schuetz E, Dolan ME, Ramírez J, Relling M, Chen P, Das S, Rosner GL, Ratain MJ.

J Clin Oncol. 2009 Jun 1;27(16):2604-14. doi: 10.1200/JCO.2008.20.6300. Epub 2009 Apr 6.

Supplemental Content

Support Center